

AT A GLANCE

NASDAQ: GILD
 Founded: 1987
 HQ: Foster City, CA

\$94.33B
 Market Cap
 (as of 5/1/2018)



~10,000
 Employees



Presence in
>35 Countries
 across
6 Continents



4 Primary Therapeutic
 Areas of Focus:

- HIV
- Liver Disease
- Oncology
- Inflammation

1Q18 FINANCIALS

PRODUCT REVENUE

\$5.0B

NON-GAAP EPS

\$1.48

OPERATING CASH FLOW

\$2.3B


Kite
 A GILEAD Company

Sangamo
 THERAPEUTICS

"We believe Sangamo's zinc finger nucleases provide the optimal gene editing platform, and we look forward to working with Sangamo to accelerate our efforts to develop next-generation autologous cell therapies, as well as allogeneic treatments that can be accessed more conveniently in the hospital setting for people living with cancer."

John F. Milligan, PhD
 Gilead's President and
 Chief Executive Officer

SELECTED PIPELINE PRODUCT CANDIDATES



COMMERCIAL PORTFOLIO HIGHLIGHTS

Human Immunodeficiency Virus (HIV)

Treatment:



Prevention:



Hepatitis C Virus (HCV)



Hepatitis B Virus (HBV)



Hematology / Oncology



ANALYST COVERAGE

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, Citi, Cowen & Company, Credit Suisse, Deutsche Bank, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Leerink Partners, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, Oppenheimer, RBC, Standard and Poors, UBS, Wells Fargo